Halozyme Therapeutics Announces Executive and Board Changes
Ticker: HALO · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, compensation
Related Tickers: HALO
TL;DR
Halozyme shakes up exec team and board, new comp plans in play.
AI Summary
On February 11, 2025, Halozyme Therapeutics, Inc. announced changes in its executive team, including the departure of certain officers and the election of new directors. The company also reported on compensatory arrangements for its officers. Specific details regarding the individuals involved and the financial implications of these arrangements were not fully disclosed in this initial filing.
Why It Matters
Changes in executive leadership and board composition can signal shifts in company strategy or operational focus, potentially impacting future performance and shareholder value.
Risk Assessment
Risk Level: medium — Executive and board changes, especially without immediate detailed explanations, can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- February 11, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of incorporation
- 12390 El Camino Real (address) — Business address
- San Diego (city) — Business address city
- 92130 (zip_code) — Business address zip
- 001-32335 (sec_file_number) — Commission File Number
FAQ
What specific roles have been affected by the departure of officers?
The filing indicates the departure of certain officers but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing states that directors have been elected but does not name them in this summary section.
What are the key terms of the compensatory arrangements for officers?
The filing mentions compensatory arrangements for certain officers but does not provide specific details on the terms.
What is the effective date of these changes?
The earliest event reported is February 11, 2025.
Where is Halozyme Therapeutics, Inc. incorporated?
Halozyme Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-13 16:30:46
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
Filing Documents
- halo-20250211.htm (8-K) — 29KB
- halo-20250211_g1.jpg (GRAPHIC) — 15KB
- 0001159036-25-000005.txt ( ) — 177KB
- halo-20250211.xsd (EX-101.SCH) — 2KB
- halo-20250211_lab.xml (EX-101.LAB) — 21KB
- halo-20250211_pre.xml (EX-101.PRE) — 12KB
- halo-20250211_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: February 13, 2025 By: /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary